Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFMO and Sulindac for Prevention of Colorectal Adenomas
NCT00118365Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 1998
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Colorectal Adenoma (CRA) and colorectal cancer (CRC) comparing Eflornithine + Sulindac with Placebo (2 arms). Primary endpoint: Detection of Any Adenoma at the End of the Study at 36 months. Started Jul 1998; status: completed.
02
Drugs
eflornithinesulindac
03
Conditions
Colorectal Adenoma (CRA)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00118365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118365.